(Q31923186)

5 July 2017

title

A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists (English)

1 reference

5 July 2017

G Vauquelin

1

1 reference

5 July 2017

P Morsing

2

1 reference

5 July 2017

F L Fierens

3

1 reference

5 July 2017

J P De Backer

4

1 reference

5 July 2017

P M Vanderheyden

5

1 reference

5 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

5 July 2017

published in

Biochemical Pharmacology

1 reference

5 July 2017

volume

61

1 reference

5 July 2017

issue

3

1 reference

5 July 2017

page(s)

277-284

1 reference

Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor.

5 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Quantitative studies of antagonists for 5-hydroxytryptamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Binding characteristics of [(3)H]-irbesartan to human recombinant angiotensin type 1 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Amino acids of the third transmembrane domain of the AT1A angiotensin II receptor are involved in the differential recognition of peptide and nonpeptide ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesar

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900546-3

10.1016/S0006-2952(00)00546-3

7 January 2021

Identifiers

DOI

1 reference

5 July 2017

1 reference